Human structural congenital malformations are the leading cause of infant mortality in the
United States. Estimates from the United States Center for Disease Control and Prevention …

During its fourth transporter workshop in 2021, the International Transporter Consortium
(ITC) provided updates on emerging clinically relevant transporters for drug development …

Background A preliminary safety signal for neural-tube defects was previously reported in
association with dolutegravir exposure from the time of conception, which has affected …

Neural tube defects (NTDs) are a classic example of preventable birth defects for which
there is a proven‐effective intervention, folic acid (FA); however, further methods of …

Background Dolutegravir (DTG) is a preferred regimen for all people with HIV including
pregnant women, but its effects on the fetus are not fully understood. Periconceptional …

Background Due to the critical role of folates in neurodevelopment, it is important to
understand potential interactions between anti-HIV drugs used during pregnancy, and folate …

Children born to mothers, with or at risk, of human immunodeficiency virus type-1 (HIV-1)
infection are on the rise due to affordable access of antiretroviral therapy (ART) to pregnant …

Dolutegravir (DTG) is an antiretroviral drug of the integrase strand transfer inhibitor (INSTI)
class used to treat human immunodeficiency virus infection. It is the recommended first-line …

Abstract Background Each year, approximately 1.1 million children are exposed in utero to
human immunodeficiency virus antiretrovirals, yet their safety is often not well characterized …

Objectives: In 2018, the Botswana Tsepamo Study reported a nine-fold increased risk of
neural tube defects in infants whose mothers were treated with dolutegravir (DTG) from the …